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Abstract Interindividual variability in drug response is a
major clinical problem. Polymedication and genetic poly-
morphisms modulating drug-metabolising enzyme activi-
ties (cytochromes P450, CYP) are identified sources of
variability in drug responses. We present here the relevant
data on the clinical impact of the major CYP polymor-
phisms (CYP2D6, CYP2C19 and CYP2C9) on drug ther-
apy where genotyping and phenotyping may be considered,
and the guidelines developed when available. CYP2D6 is
responsible for the oxidative metabolism of up to 25 % of
commonly prescribed drugs such as antidepressants, anti-
psychotics, opioids, antiarrythmics and tamoxifen. The
ultrarapid metaboliser (UM) phenotype is recognised as a
cause of therapeutic inefficacy of antidepressant, whereas
an increased risk of toxicity has been reported in poor
metabolisers (PMs) with several psychotropics (desipra-
mine, venlafaxine, amitriptyline, haloperidol). CYP2D6
polymorphism influences the analgesic response to prodrug
opioids (codeine, tramadol and oxycodone). In PMs for
CYP2D6, reduced analgesic effects have been observed,
whereas in UMs cases of life-threatening toxicity have
been reported with tramadol and codeine. CYP2D6 PM
phenotype has been associated with an increased risk of
toxicity of metoprolol, timolol, carvedilol and propafenone.
Although conflicting results have been reported regarding
the association between CYP2D6 genotype and tamoxifen
effects, CYP2D6 genotyping may be useful in selecting
adjuvant hormonal therapy in postmenopausal women.
CYP2C19 is responsible for metabolising clopidogrel,
proton pump inhibitors (PPIs) and some antidepressants.
Carriers of CYP2C19 variant alleles exhibit a reduced
capacity to produce the active metabolite of clopidogrel,
and are at increased risk of adverse cardiovascular events.
For PPIs, it has been shown that the mean intragastric pH
values and the Helicobacter pylori eradication rates were
higher in carriers of CYP2C19 variant alleles. CYP2C19 is
involved in the metabolism of several antidepressants. As a
result of an increased risk of adverse effects in CYP2C19
PMs, dose reductions are recommended for some agents
(imipramine, sertraline). CYP2C9 is responsible for meta-
bolising vitamin K antagonists (VKAs), non-steroidal anti-
inflammatory drugs (NSAIDs), sulfonylureas, angiotensin
II receptor antagonists and phenytoin. For VKAs, CYP2C9
polymorphism has been associated with lower doses,
longer time to reach treatment stability and higher fre-
quencies of supratherapeutic international normalised
ratios (INRs). Prescribing algorithms are available in order
to adapt dosing to genotype. Although the existing data are
controversial, some studies have suggested an increased
risk of NSAID-associated gastrointestinal bleeding in car-
riers of CYP2C9 variant alleles. A relationship between
CYP2C9 polymorphisms and the pharmacokinetics of
sulfonylureas and angiotensin II receptor antagonists has
also been observed. The clinical impact in terms of hypo-
glycaemia and blood pressure was, however, modest.
Finally, homozygous and heterozygous carriers of CYP2C9
variant alleles require lower doses of phenytoin to reach
therapeutic plasma concentrations, and are at increased risk
of toxicity. New diagnostic techniques made safer and
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easier should allow quicker diagnosis of metabolic varia-
tions. Genotyping and phenotyping may therefore be con-
sidered where dosing guidelines according to CYP
genotype have been published, and help identify the right
molecule for the right patient.
1 Introduction
Interindividual variability in drug response is a major
problem in clinical practice. Factors known to influence
drug responses are indeed either intrinsic (age, gender,
race/ethnicity, disease states, organ dysfunctions) or
extrinsic/environmental (smoking, diet, concomitant
medications) [1]. Genetics is another source of interindi-
vidual variability known to influence drug response.
Indeed, considering that 60 to 80 % of commercialised
drugs are metabolised by polymorphic enzymes, adverse
drug reactions (ADRs) as well as therapeutic failure may
be attributed to genetic variations in drug-metabolising
enzymes.
A US meta-analysis estimated that the incidence of
serious side effects is 6.7 % and 100,000 deaths are yearly
due to ADRs [2]. The associated costs are considerable
(US$100 billion). Up to 7 % of hospitalisations are due to
ADRs in the UK and 13 % in Sweden [3, 4]. Conversely, it
was reported that 25–60 % of common drug therapies were
successful [5]. Polymedication is another well-established
source of variability in drug response in the elderly popu-
lation [1]. The cytochromes P450 (CYP) involved in the
metabolism of various substrates are presented in Table 1,
and drug-inhibiting or drug-inducing CYP are listed in
Table 2. Drug interactions may indeed mimic genetic
defects (such as with CYP inhibitors) or increased metab-
olism (CYP inducers).
In order to assess the clinical importance, a number of
factors need to be taken into account. The clinical impact
of a given polymorphism will depend on whether the
pathway is major, whether it leads to an active metabolite
and its relative potency compared to the parent drug, on the
therapeutic window of the drug and on the presence of
other pathways of elimination. Phenotyping and/or geno-
typing should allow the identification of patients at risk of
inefficacy or toxicity and offer tools to individualise drug
prescription.
We performed a review by means of a structured com-
puterised search in the Medline database (1966–2012).
Keywords were pharmacogenetics, polymorphism, drug
interactions, cytochrome P450 (CYP), CYP2D6, CYP2C9,
CYP2C19, phenotyping, genotyping, and the relevant
drugs and therapeutic classes discussed hereafter. Articles
in English and French were selected. References in relevant
articles were also retrieved.
2 Clinical Impact of CYP450 Polymorphisms
on Drug Therapy
The cytochromes P450 (CYP) are a group of isoenzymes
located primarily in the endoplasmic reticulum of hepatic
cells. They catalyse oxidative or reductive reactions of
endogenous lipophilic (steroids, bile acids, fatty acids,
prostaglandins) and exogenous compounds (drugs) into
more polar (hydrophilic) products, allowing their elimina-
tion in the urine. The human genome comprises 57 CYP
genes which are classified according to sequence homology
into 18 families and 44 subfamilies [6]. The CYP 1 to 3
families are involved in phase I drug metabolism, whereas
CYP 4 to 51 are associated with endobiotic metabolism.
2.1 Cytochrome P450 2D6 and Clinical Impact
Even though CYP2D6 only represents 1–5 % of the CYP
liver content, it is responsible for the oxidative metabolism
of up to 25 % of commonly prescribed drugs such as
antidepressants, antipsychotics, opioids, antiarrythmics and
tamoxifen, many of which have a narrow therapeutic
window [7–9]. CYP2D6 is encoded by a highly polymor-
phic gene, with more than 70 alleles and 130 genetic
variations described [10]. Marked interethnic variation in
the frequency of the various alleles has been reported
[9, 11, 12] and are available in various online databases
(dbSNP [13], ALFRED [14], 1000 Genomes [15]). Indi-
viduals can be distinguished into four phenotypic groups
which are predicted by the number of functional alleles.
Poor metabolisers (PMs) carry two null alleles responsible
for an absent enzymatic activity. They represent 5–10 % of
the Caucasian population, whereas this phenotype is rare in
Asians and highly variable in those of African ancestry
[12, 16]. In Europe, 95–99 % of PMs are detected by
screening the main null alleles *3, *4, *6 and the gene deletion
*5 [17]. The null allele CYP2D6*4 (splice defect) is present in
12–21 % of the Caucasians but only in 1–2 % of Asians
and Africans. Intermediate metabolisers (IMs) carry a
combination of either a null allele or two deficient alleles.
The common deficient alleles are CYP2D6*9, *10, *17 and
*41 [16]. IMs represent 10–15 % of Caucasians but are
much more frequent in Asians (up to 50 %) because of the
high prevalence of the defective allele *10, and up to 30 %
of Africans in whom the allele *17 is frequent. The carriers
of gene duplications or multi-duplications are assigned to
the ultrarapid metaboliser (UMs) phenotype (1–10 % of
Caucasians) [18]. UMs are more prevalent in the Southern
European countries (Spain 7–10 %, Sicily 10 % vs Sweden
1–2 %). Gene duplications are described in 20 % of Saudi
Arabians and 29 % of Ethiopians. The extensive meta-
bolisers (EMs) have normal enzymatic activity and repre-
sent 60–85 % of the Caucasian population.
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Table 1 Substrates of cytochromes P450 (CYP). Substrates are classified in alphabetical order according to their International Nonproprietary
Name (non-exhaustive list). A dark green square indicates a major metabolic pathway and a light green square a minor metabolic pathway
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Table 2 Inhibitors and Inducers of cytochromes P450 (CYP).
Inhibitors and inducers are classified in alphabetical order according
to their International Nonproprietary Name. Inhibition/induction
strength is indicated by a dark green square (potent) or light green
square (weak). The impact of the interaction will depend on the
importance of the metabolic pathway for the substrate
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2.1.1 Psychotropic Agents
Various psychotropic agents are metabolised at least in part
by CYP2D6. Depending on the pharmacokinetic (PK) and
the pharmacodynamic (PD) properties of the drug, the
impact of the polymorphism will be more or less pro-
nounced. UMs may require higher doses to achieve thera-
peutic drug levels and effects, whereas PMs might be at
increased risk of toxicity. The association between
CYP2D6 PM phenotype and psychotropic agent toxicity
(antidepressants, antipsychotics) has been described [19,
20]. PMs were twice as frequent amongst patients pre-
senting ADRs (44 vs 21 %) [19]. Patients treated with
CYP2D6 substrates (tricyclics, thioridazine, perphenazine,
haloperidol, risperidone) experienced a higher rate of
ADRs that was in turn associated with the CYP2D6
genotype (PM [ IM [ EM [ UM) [20]. The costs asso-
ciated with the treatment of the metabolic extremes (PM
and UM) were US$4,000 to 6,000 per year higher than
those of EM and IM on the same treatments, and the length
of hospitalisation was also longer in PMs [20]. Kirchheiner
et al. systematically analysed all pharmacogenetic data
available on the impact of genetic polymorphisms on the
positive effects of and adverse reactions to 36 antidepres-
sants and 38 antipsychotics. CYP2D6 polymorphism was
found to be relevant for 14 out of 36 antidepressants,
requiring at least doubling of the dose in EMs in compar-
ison to PMs, and for one third of the assessed antipsy-
chotics [21].
2.1.1.1 Antidepressants Most antidepressants, selective
serotonin recapture inhibitors (SSRIs), non-selective
recapture inhibitors (NSRIs) or tricyclic agents (TCAs) are
metabolised by CYP2D6. The UM phenotype is now
recognised as a cause of therapeutic ‘‘resistance or ineffi-
cacy’’ and higher antidepressant doses are necessary to
obtain efficacy [22]. The relationship between persistent
mood disorders and CYP2D6 gene duplication was inves-
tigated in 108 patients. UM subjects were over-represented
in the non-responders group as compared to control pop-
ulation [23]. On the other hand, the clearances of nortrip-
tyline, clomipramine, desipramine, imipramine,
trimipramine, amitriptyline, paroxetine, fluvoxamine, flu-
oxetine and venlafaxine are reduced in PMs [18, 24]. In a
prospective study, all the patients experiencing toxicity
(confusion, sedation, orthostatic hypotension) after desi-
pramine administration (100 mg/day for 3 weeks) were
PMs and the dose consequently had to be reduced [25]. An
association between the PM phenotype and venlafaxine
cardiotoxicity (palpitation, shortness of breath, arrhythmia)
[24] and amitriptyline toxicity [26] was furthermore sug-
gested. The antidepressant effective dose was shown to
vary between the two extremes PM and UM from 10 to up
to 500 mg/day for nortriptyline, 10–500 mg/day for ami-
triptyline and 25–300 mg/day for clomipramine [24]. In
Asian populations (mostly IMs), it was demonstrated that
metabolism of some antidepressants (desipramine, nor-
triptyline, clomipramine) was reduced and that they
received lower antidepressant doses [24]. Kirchheiner et al.
developed the first antidepressant dose recommendations
based on CYP2D6 genotype/phenotype and PK parameters
in Caucasians. The mean dose reduction was 50–80 % for
some tricyclics in PMs, and 30 % for some SSRIs. In UMs,
the recommended increase in dose was 260 % for desi-
pramine, 300 % for mianserin and 230 % for nortriptyline
[27].
The Pharmacogenetics Working Group of the Royal
Dutch Pharmacists Association established dose recom-
mendations for several TCAs, SSRIs and NSRIs on the
basis of CYP2D6 genotype [28] (Table 3). Clomipramine,
imipramine and nortriptyline dose should be reduced by
50–70 % in PMs and plasma concentrations should be
monitored, whereas in UMs an alternative drug may be
considered, plasma concentrations monitored or dose
increased. No dose adjustment is necessary for paroxetine
in PMs and insufficient data are available in UMs.
Regarding venlafaxine, insufficient data are available in
PMs and the recommendation is to select an alternative
drug or adjust dose to clinical response and monitor plasma
concentration. In UMs, authors recommend to be alert to
decreased venlafaxine and increased O-desmethyl-venla-
faxine plasma concentration, and to titrate the dose to a
maximum of 150 % of the normal dose or select an alter-
native drug. Regarding duloxetine, no recommendations
exist at this time. Insufficient data are available to allow
calculation of dose adjustment for the other molecules.
2.1.1.2 Neuroleptics The PM phenotype has been asso-
ciated with a reduction of the elimination of various anti-
psychotics such as haloperidol, perphenazine and
zuclopenthixol. Their clearance decreased (two- to three-
fold) in CYP2D6 PMs and their half-life was prolonged
[29]. A prospective multicentric study in 175 patients with
psychotic symptoms treated with haloperidol demonstrated
an inverse correlation between therapeutic efficacy and the
number of active CYP2D6 genes and ADRs were more
frequent in PMs [30]. In a retrospective study, during the
first days of treatment with phenothiazine or haloperidol,
33 % of the patients with severe side effects were PMs
[29]. In older patients with dementia treated by perphena-
zine, side effects were also more frequent in PMs after
10 days of treatment [29]. Deficient CYP2D6 alleles were
more prevalent in patients with tardive dyskinesia and
parkinsonism on neuroleptics and pseudo-parkinsonism
was significantly more frequent in PMs after haloperidol
treatment [29, 30]. These authors suggested that PMs
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should receive half the dose of haloperidol. Furthermore,
PMs have been shown to be at fourfold higher risk of
starting anti-parkinsonism treatment after being treated
with antipsychotics metabolised by CYP2D6 [30]. How-
ever, a study estimated that 20 patients would have to be
genotyped so that 1 patient would benefit from the treat-
ment [31]. Another retrospective study (241 patients)
showed that anti-parkinson drugs were given twice as
frequently in PMs [32]. In Asians, haloperidol and
clozapine doses were shown to be lower than those in
Caucasians, and toxicity appeared at a lower dose [24]. A
meta-analysis of eight case-control studies including 569
patients (220 cases with tardive dyskinesia and 349 con-
trols) aimed at evaluating the association between CYP2D6
alleles and susceptibility to tardive dyskinesia in treated
schizophrenia. PMs had a 43 % higher risk of developing
tardive dyskinesia as compared to EMs [odds ratio
(OR) = 1.43, 95 % confidence interval (CI) 1.06–1.93,
P = 0.021] [33]. The Pharmacogenetics Working Group of
the Royal Dutch Pharmacists Association established dose
recommendations for haloperidol, risperidone and zuc-
lopenthixol on the basis of CYP2D6 genotype [28] (Table 3).
Dose should be reduced by 50 % in PMs or an alternative drug
selected, whereas in UMs the authors recommend to be extra
alert to diminished plasma concentrations or to select an
alternative drug. No dose adjustment is needed for aripipraz-
ole, clozapine, flupentixol and olanzapine.
2.1.2 Opioids
The influence of CYP2D6 polymorphisms on the analgesic
response and therapeutic outcome to a number of prodrug
opioids is now established. The opioids codeine, tramadol
and oxycodone have to be activated by CYP2D6 into their
active moieties, morphine [34, 35], O-desmethyl-tramadol
(M1) [36] and oxymorphone [37, 38], respectively. The
impact of CYP2D6 polymorphisms have been assessed in
terms of PK and PD consequences.
In PMs for CYP2D6, reduced or absent metabolite for-
mation and reduced analgesic effects have been observed
after codeine [39], tramadol [40] and oxycodone adminis-
tration [37, 38]. A cohort study showed that children
having ineffective pain treatment of sickle cell crisis with
codeine were more likely to have reduced CYP2D6 activity
[39]. After major abdominal surgery, non-response rates to
tramadol were fourfold higher amongst PMs than other
CYP2D6 genotypes in a randomised prospective study
[40]. In healthy volunteers, PMs experienced no analgesic
effect after oxycodone administration in the experimental
pain setting [38].
Conversely the CYP2D6 UM phenotype has been
associated with quicker analgesic effects but higher
mu-opioid-related toxicity after tramadol [41, 42] or
oxycodone administration [38, 43]. The risk of codeine use
in paediatrics and breastfed neonates in association with
UM genotype has been reported with four fatal cases and
serious toxicity cases [44–49]. The FDA released a warn-
ing in August 2007 that codeine use by nursing mothers
may increase toxicity in infants [50], and more recently
about the risk of death after the use of codeine in infants for
tonsillectomy/adenoidectomy in August 2012 [51]. In
February 2013, the FDA stated that a new Boxed Warning
and Contraindication were to be added to the drug label of
codeine-containing products [52].
Clinical Pharmacogenetics Implementation Consortium
(CPIC) guidelines for codeine therapy in the context of
CYP2D6 phenotype were recently published [53]. CPIC
was established in order to provide drug-dosing guidelines
based on an individual’s genotype. These peer-reviewed
gene–drug guidelines are published and updated periodi-
cally on the PharmGKB website [54]. The authors rec-
ommendation is to avoid codeine use in UM and PM for
CYP2D6 and consider alternative analgesics such as mor-
phine. The classification of recommendation is labelled as
‘‘strong’’. The Dutch Pharmacogenetics Working Group
Guideline edited the same recommendation for codeine,
tramadol and oxycodone [28].
CYP activity is modulated by inhibitors mimicking a
genetic deficiency (PM phenotype) (Table 2). CYP2D6
inhibitors such as quinidine have been associated with a
reduction of codeine, tramadol and oxycodone analgesic
effects [34, 36, 38]. Importantly, drug interactions modu-
lating the activity of the enzymes involved in the other
pathways of elimination have to be taken into account.
Indeed, they have the ability to modify the therapeutic
index of a drug or its pharmacological properties, espe-
cially in the context of a genetic polymorphism. The
co-administration of oxycodone with the CYP3A inhibitor
ketoconazole (Table 2) has been associated with a dramatic
increase in oxycodone efficacy (experimental pain setting)
and toxicity, with this effect being even more pronounced
in the UM for CYP2D6 [38]. Similarly a CYP3A inhibitor
co-administrated with codeine induced a life-threatening
opioid intoxication in a CYP2D6 UM [55].
The pharmacological properties of the dual opioidergic
and monoaminergic tramadol [56] may also be modified as
a consequence of CYP activity modulation by drug inter-
actions and/or genetic polymorphisms. In CYP2D6 PMs,
tramadol properties will move towards a monoaminergic
antidepressant-like molecule devoid of opioidergic activity,
whereas the opioidergic properties will be more pro-
nounced in CYP2D6 UM. Different pharmacological
effects will therefore be expected depending on the activity
of CYP2D6. Some authors have summarised recommen-
dations on the usage of opioids while administrating
CYP3A and 2D6 inhibitors, and CYP3A inducers [57]
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Codeine CYP2D6 EM: standard starting dose of codeinea
PM: avoid codeine, choose alternative analgesics (morphine or a non-opioid), avoid tramadola
Analgesia: select alternative drug *or be alert to symptoms of insufficient pain reliefb
Cough: nob
IM: monitored closely for less than optimal response, alternative analgesic if required. Begin with 15–60 mg every
4 h as needed for pain. If no response, consider alternative analgesics such as morphine or a non-opioid. Monitor
tramadol use for responsea
Analgesia: select alternative drug* or be alert to symptoms of insufficient pain reliefb
Cough: nob
UM: avoid codeine (toxicity). Alternative analgesics (morphine or a non-opioid). Avoid tramadola
Analgesia: select alternative drug *or be alert to ADEsb
Cough: be extra alert to ADEs due to increased morphine plasma concentrationb
*(e.g. acetaminophen, NSAID, morphine—not tramadol or oxycodone)
Oxycodone CYP2D6 PM: alternative drug (not tramadol or codeine) or be alert to symptoms of insufficient pain reliefb
UM: be alert to ADEsb
Tramadol CYP2D6 PM and IM: alternative drug (not oxycodone or codeine) and/or be extra alert to insufficient pain reliefb
UM: dose reduction by 30 %, be alert for ADEs, or alternative drug (not oxycodone or codeine)b
Antiarrythmics CYP2D6 Metoprolol and propafenoneb
PM: dose reduction by 70–75 % or alternative drug, record ECG, monitor plasma concentration
IM: dose reduction by 50 % or alternative drug
UM: alternative drug or titration to a maximum of 250 % of the normal metoprolol dose; insufficient data to allow
propafenone dose adjustment calculation but adjust to plasma concentration, record ECG or select alternative drug
Flecainideb
PM: dose reduction by 50 %, record ECG, monitor plasma concentration
IM: dose reduction by 25 %, record ECG, monitor plasma concentration
UM: dose reduction and monitor plasma concentration or select alternative drug (e.g. sotalol, disopyramide,
quinidine, amiodarone)
Carvedilol
No recommendation at this timeb
Antidepressants CYP2D6 Clomipramine and imipramine
Dose should be reduced by 50 to 70 % in PMs and plasma concentrations should be monitored; in UM an alternative
drug (*e.g. citalopram, sertraline) may be considered, plasma concentrations monitored or increase imipramine dose
by 70 %b
Amitriptyline
PM and UM: select alternative drug* or monitor plasma concentration
IM: dose reduction by 25 % and monitor plasma concentration or select alternative drug*b
Nortriptyline
PM (IM): reduce dose by 60 (40) % and monitor plasma concentrations
UM: select alternative drug *or increase dose by 60 % and monitor plasma concentrationsb
Venlafaxine
PM, IM: insufficient data to allow calculation of dose adjustment, select an alternative drug or adjust dose to clinical
response and monitor plasma concentration
UM: titrate dose to a maximum of 150 % of the normal dose or select an alternative drug*b
Doxepine
PM (IM): reduce dose by 60 (20) %. Monitor plasma concentration
UM: select alternative drug* or increase dose by 100 %b
Paroxetine
PM, IM: no dose adjustment
UM: select alternative drug*b
Duloxetine, mirtazapine
No dose adjustment recommendationsb






All genotypes: select alternative (e.g. quetiapine, olanzapine, clozapine) or be extra alert to ADE and adjust dose to
clinical responseb
Aripriprazole
PM: reduce maximum dose to 10 mg/day
IM, UM: no recommendationb
Zuclopenthixol
PM: reduce dose by 50 % or select alternative drug
IM: reduce dose by 25 % or select alternative
UM: insufficient data to allow calculation of dose adjustment, be alert to low plasma concentrations or select
alternativeb
Haloperidol
PM: reduce dose by 50 % or select alternative (e.g. pimozide, flupenthixol, fluphenazine, quetiapine, olanzapine,
clozapine)
IM: none
UM : insufficient data to allow calculation of dose. Be alert to decreased haloperidol plasma concentration and adjust
maintenance dose in response to haloperidol plasma concentration or select alternativeb
Clozapine, flupentixol and olanzapine
No dose adjustment neededb




Two algorithms estimating stable warfarin dose across different ethnic populations [Articles: 18305455, 19228618]a
Daily warfarin doses recommendations based on CYP2C9 and VKORC1 genotype (warfarin product insert approved
by the FDA)a
Acenocoumarol
*1/*2: check INR more frequentlyb
*2/*2, *1/*3, *2/*3, *3/*3: check INR more frequently after initiating or discontinuing NSAIDsb
Phenprocoumon
*1/*2, *1/*3: noneb
*2/*2, *2/*3, *3/*3: check INR more frequentlyb
Phenytoin CYP2C9 *1/*2, *1/*3: maintenance dose reduction by 25 %b
*2/*2, *2/*3, *3/*3: maintenance dose reduction by 50 %b
Evaluate response and serum concentration after 7–10 days. Be alert to ADEs (e.g. ataxia, nystagmus, dysarthria,
sedation)b
Sulfonylureas CYP2C9 Glibenclamide, glimepiride, gliclazide, tolbutamide
No adaptation of dosage is recommendedb
Clopidogrel CYP2C19 UM, EM: clopidogrel label-recommended dosage and administrationa,b
IM, PM: prasugrel or other alternative therapy (if no contraindication)a
Consider alternative drug. Prasugrel is not, or to a much smaller extent, metabolised by CYP2C19 but is associated
with an increased bleeding risk compared to clopidogrelb
Proton pump
inhibitors
CYP2C19 Esomeprazole, lansoprazole, omeprazole, pantoprazole
UM: be extra alert to insufficient response, dose increase by 50–400 %b
PM, IM: no dose recommendationb
Rabeprazole
No dose recommendationb
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(Table 2). The recommendation is to avoid the combina-
tion of oxycodone and CYP3A inhibitors as well as
CYP3A inducers and to monitor patients on oxycodone
with a CYP2D6 inhibitor. Regarding codeine, the authors’
recommendations are to avoid the co-administration of a
CYP2D6 inhibitor or consider alternative pain treatment,
and to monitor if administration is concomitant with a
CYP3A inhibitor or inducer. Codeine should be avoided
when a CYP3A inhibitor is co-prescribed in a highly sus-
ceptible population (such as UM for CYP2D6) [57]. The
importance of these pharmacogenetic modulations of drug
interactions in the clinical setting needs to be further
investigated.
2.1.3 Antiarrhythmic Agents
CYP2D6 is involved in the metabolism of carvedilol,
bufuralol, metoprolol, propranolol and timolol. CYP2D6
genetic polymorphism has an impact on the disposition of
metoprolol, bufuralol and timolol, whereby PMs have a
higher exposure (four- to sixfold), higher plasma concen-
trations (two- to fivefold) and a prolonged half-life (two- to
threefold). The PM genotype has furthermore been asso-
ciated with an increased risk of toxicity after metoprolol
administration [22, 58] and some authors demonstrated that
PMs had a fivefold higher risk of developing adverse
effects [59]. The increased efficacy or higher risk of tox-
icity in PMs was furthermore demonstrated after timolol
(more pronounced heart rate reduction) [60], carvedilol
(reduction of the systolic blood pressure) [61], propafenone
(central side effects five times more pronounced and
increased QRS narrowing at a given concentration)
administration [62]. After propranolol administration, an
open study did not show any difference in the PK param-
eters or the clinical response depending on CYP2D6 phe-
notype [60]. The Dutch Pharmacogenetics Working Group
Guideline recommended a 70–75 % reduction of meto-
prolol and propafenone in PMs or alternative drug selection
[28]. In UMs, an alternative drug should be selected or
metoprolol dose titrated to a maximum of 250 % of the
normal dose. Insufficient data are available to allow cal-
culation of dose adjustment for propafenone but the rec-
ommendation is to adjust dose to plasma concentration and
record ECG or select an alternative drug.
A double-blind randomised control study assessed the
PK and PD consequences of concomitant administration of
carvedilol and a CYP2D6 inhibitor (fluoxetine) in cardiac
failure. Fluoxetine stereospecifically inhibited (R)-(?)-
carvedilol, but had no clinical impact on the side effects,
heart rate and blood pressure in this pilot study [63].
In healthy volunteers receiving metoprolol, after the





Antidepressants CYP2C19 Citalopram, escitalopramb
UM: monitor plasma concentration and titrate dose to a maximum of 150 % in response to efficacy and adverse drug
event or select alternative drug (e.g. fluoxetine, paroxetine)
PM and IM: none
Sertralineb
PM: reduce dose by 50 %
IM: insufficient data to allow calculation of dose adjustment. Be extra alert to adverse drug events (e.g. nausea,
vomiting, diarrhoea)
UM: none (no data were retrieved)
Imipramineb
PM: reduce dose by 30 % and monitor plasma concentration of imipramine and desipramine or select alternative
drug (e.g. fluvoxamine, mirtazapine)
IM: insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g. fluvoxamine, mirtazapine)
UM: no data
Moclobemideb
No recommendations at this time
Voriconazole CYP2C19 PM or IM: monitor serum concentrationb
UM: noneb
ADEs adverse drug events, CYP cytochrome P450, EM extensive metaboliser, UM ultrarapid metaboliser, IM intermediate metaboliser, PM poor
metaboliser, INR international normalised ratio, FDA US Food and Drug Administration
a According to the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network (CPIC)
b According to the Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association
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20 mg/day, both (S)- and (R)-metoprolol AUC increased
three- and fourfold, respectively, and the half-life of both
isomers increased by approximately twofold. The decrea-
ses of the heart rates and systolic blood pressures were
significantly more pronounced after paroxetine adminis-
tration [64]. Similarly, acute myocardial infarction patients
treated with metoprolol and paroxetine had a significant
metoprolol AUC increase, and a reduction of metoprolol
dose was required in two patients owing to excessive
bradycardia and severe orthostatic hypotension [65].
2.1.4 Tamoxifen
Tamoxifen is approved in the treatment of metastatic breast
cancer as well as an adjuvant therapy of breast cancer in
postmenopausal women. The two active metabolites of
tamoxifen produced predominantly by CYP2D6 as well as
CYP3A are 4-hydroxytamoxifen and endoxifen; their
affinity for the oestrogen receptor is 100 times higher than
tamoxifen and their potency is 30- to 100-fold greater [66,
67]. Endoxifen is considered the most clinically relevant
active metabolite in terms of anticancer effect and hormone
receptor blockade. Endoxifen plasma concentrations in
newly diagnosed breast cancer CYP2D6 PM and IM gen-
otyped women were 26 and 55 % of those in EMs,
respectively [68]. The same was shown in CYP2D6 PMs
owing to drug inhibition by paroxetine [69]. Thirty-nine
and 9 % of the variability of steady-state concentrations of
endoxifen and 4-hydroxytamoxifen, respectively, were
explained by CYP2D6 genotypes and among PMs 93 %
had endoxifen levels below IC90 values [70]. PMs are
therefore likely to experience therapeutic failure after
tamoxifen, whereas UMs might be prone to increased
toxicities [71]. Homozygous CYP2D6*4 carriers (PMs)
were shown to have increased risk of breast cancer recur-
rence, shorter relapse-free periods and worse event-free
survival rates as compared to carriers of functional alleles
[72–74]. The impact of CYP2D6*10 homozygotes (IMs) on
the PK and PD behaviour of tamoxifen was assessed in
Asians [75–78] . CYP2D6*10/*10 has lower endoxifen and
4-OH-tamoxifen concentrations, shorter median time to
progression, and higher incidence of recurrence within
10 years after the operation. The FDA has recommended
labelling change to indicate that postmenopausal oestrogen
receptor-positive breast cancer patients taking adjuvant
tamoxifen who are homozygous for CYP2D6*4 have a
significant decreased relapse-free survival as compared to
other genotypes. However no recommendation on the
routine testing of all women on tamoxifen was made, and
the impact of other deficient variants (such as CYP2D6*10)
was not addressed. A matched case-control study using the
Austrian Breast and Colorectal Cancer Study Group Trial 8
(ABCSG8) demonstrated that PMs or carriers of a deficient
allele had a higher likelihood of an event than EMs (OR
2.45 and 1.67, respectively) during the first 5 years of
therapy [79].
In 98 Japanese breast cancer patients on 20 mg tamox-
ifen daily (adjuvant setting), Kiyotani et al. evaluated the
impact of dose adjustment according to CYP2D6 genotype.
In CYP2D6*10 heterozygotes and homozygotes, the dose
was increased to 30 and 40 mg/day, respectively. The
achieved endoxifen and 4-OH-tamoxifen plasma concen-
trations were increased to similar levels as those in the
CYP2D6*1/*1 patients receiving tamoxifen 20 mg/day
[80]. The dose increase did not result in increased side
effects. However the dose increase did not lead to dose-
proportional increase in endoxifen concentrations. Others
authors demonstrated that increasing the tamoxifen dose
from 20 to 40 mg/day resulted in increased endoxifen
concentrations in PMs but not in EMs [81]. Another study
demonstrated that increasing tamoxifen dose from 20 to
30 mg in PMs was associated with a 90 % in the endoxifen
levels by day 60 and an increased antioestrogenic activity
score [82].
Conflicting results have been reported regarding the
association between CYP2D6 genotype and tamoxifen
effects. The pitfalls of these retrospective studies (small
cohorts, limited CYP2D6 allele coverage, quality of
genotyping, correct genotype–phenotype assignment) were
pointed out by several authors [83, 84]. Two large pro-
spective studies (The Breast International Group BIG 1-98
trial and the Arimidex, Tamoxifen, Alone or in Combina-
tion (ATAC) trial) were unsupportive with regard to
CYP2D6 genotyping in the adjuvant setting as no associ-
ation was demonstrated with breast cancer recurrence [85,
86]. However these two studies have been criticised as
endoxifen plasma concentrations were not measured and
drug inhibition was not taken into account (Table 2).
Pharmacogenetics experts asked for the retraction of the
BIG 1-98 study on the basis of massive departures from
Hardy–Weinberg equilibrium with the possibility of bias
introduced by the CYP2D6 genotype from the tumour
(somatic) and not the host genome (germline DNA) [83,
87]. Some authors have therefore stated that ‘‘until pro-
spective adjuvant trial data are available, the current evi-
dence is sufficient to accept the CYP2D6–tamoxifen
pharmacogenetic relationship in postmenopausal women’’
[83]. Therefore CYP2D6 genotyping may be useful in
selecting adjuvant hormonal therapy in postmenopausal
women and aromatase inhibitors might be preferred in
CYP2D6 PMs as recommended by the Pharmacogenetics
Working Group of the Royal Dutch Pharmacists Associa-
tion. Medications decreasing CYP2D6 activity, such as
antidepressants, should be avoided when prescribing
tamoxifen (Table 3). This needs to be confirmed in well-
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conducted prospective studies with tamoxifen adjuvant
therapy.
2.2 Cytochrome P450 2C19
The CYP2C19 is responsible for metabolising commonly
used drugs that include clopidogrel, proton pump inhibitors
(PPIs) and some antidepressants [11, 88]. The enzyme is
highly polymorphic. To date, at least 35 (*1B to *28)
variants and a series of subvariants of CYP2C19 have been
identified, CYP2C19*1 representing the wild-type allele
[89]. On the basis of their ability to metabolise (S)-
mephenytoin or other probe drugs, individuals can be
categorised as EM, PM or UM for CYP2C19 [90, 91].
Heterozygous EMs are sometimes also referred to as IMs.
The majority of the CYP2C19 PMs are carriers of the
variant alleles *2 and *3, which are loss of function alleles
(LOF) [90], whereas the *17 variant is a gain of function
(GOF) allele associated with increased activity [91].
Studies have shown a marked interethnic variation in the
distribution of variant alleles. The allelic frequency of
CYP2C19*2 has been shown to be 15 % in Africans,
29–35 % in Asians, 12–15 % in Caucasians and 61 % in
Oceanians. The CYP2C19*3 is mainly found in Asians
(5–9 % in Asians, less than 0.5 % in Caucasians). The
allelic frequency of CYP2C19*17 has been shown to be
16 % in Africans, 3–6 % in Asians and 16–21 % in Cau-
casians [92, 93].
2.2.1 Clopidogrel
Clopidogrel is a prodrug whose in vivo metabolite binds to
the platelet P2Y12 receptor causing irreversible blockade.
Approximately 85 % of the parent drug is inactivated by
human carboxylesterase 1, whereas the remainder is trans-
formed to the intermediate, inactive oxo-clopidogrel by
CYP2C19, CYP1A2 and CYP2B6. The CYP3A, CYP2B6,
CYP2C9 and CYP2C19 are responsible for the second-step
production of the active metabolite [94]. Many studies have
shown that carriers of certain variant alleles exhibit a
reduced capacity to produce the active metabolite and are
therefore at increased risk of adverse cardiovascular events
[92]. In 2010, the FDA added a Boxed Warning to the
clopidogrel label to emphasis that patients who are PM for
CYP2C19 are at an increased risk of adverse cardiovascular
outcomes because of a reduced effectiveness of clopidogrel
[95]. Bauer et al. [96] recently conducted a systematic
review and meta-analysis to examine the association
between CYP2C19 genotype and the clinical efficacy of
clopidogrel, in a total of 15 studies. The presence of at least
one LOF allele was associated with an increased risk of
stent thrombosis (summary OR 1.77; 95 % CI 1.31–2.40;
P \ 0.001). However, the authors did not find an
association between CYP2C19 polymorphism (LOF or
GOF allele) and the clinical efficacy of clopidogrel used to
prevent major adverse cardiovascular events (OR 1.11;
95 % CI 0.89–1.39; P = 0.36 for carriers of at least one
LOF allele, and OR 0.93; 95 % CI 0.75–1.14; P = 0.48 for
carriers of a GOF allele). In contrast, in a more recent meta-
analysis that included 16 studies, the presence of at least one
LOF allele was associated with a significant increase in
adverse clinical events which were defined as a composite
endpoint of death, myocardial infection, stent thrombosis or
ischaemic stroke (OR 1.42; 95 % CI 1.13–1.78) [97]. Evi-
dence supports an effect of CYP2C19 genotype on protec-
tion from major adverse cardiovascular outcomes for acute
coronary syndrome/percutaneous coronary intervention, but
not for lower-risk conditions [98]. Therefore, despite the
large number of studies published, guiding clopidogrel
dosing on the basis of CYP2C19 genotype is still a matter of
debate [99] (Table 3).
2.2.2 Proton Pump Inhibitors
Proton pump inhibitors are used to treat acid-related dis-
orders such as gastro-oesophageal reflux disease or
oesophagitis/gastritis. Furthermore, PPIs are the treatment
of choice for Helicobacter pylori infection, in combination
with antibiotics. They undergo hepatic metabolism via the
CYP450 pathways and the isoforms CYP2C19 and
CYP3A4 in particular [100]. As a result of the metabolic
pathways of PPIs, CYP2C19 polymorphism has an impact
on their PK behaviour and clinical efficacy. The PK
properties of PPIs (AUC, Cmax and clearance) have been
shown to be significantly different between CYP2C19 PMs
and EMs. The ratios of the mean AUC values in PMs
versus EMs for omeprazole, pantoprazole, lansoprazole
and rabeprazole were 6.3, 6, 4.3 and 1.8, respectively
[101]. These differences in terms of PK properties translate
into differences in their clinical effects. It has been shown
that the mean intragastric pH values were higher in PMs
than in EMs for both omeprazole and lansoprazole [102]. A
meta-analysis, which included 20 studies, showed a sig-
nificant difference in H. pylori eradication rates between
wild-type individuals and carriers of at least one LOF allele
(OR 2.26; 95 % CI 1.58–2.96; P \ 0.0001) when all PPI-
based therapies were combined. The difference was greater
when wild-type homozygous and variant homozygous
patients were compared (OR 2.79; 95 % CI 1.77–4.41;
P \ 0.0001). When individual agents were analysed sep-
arately, a significant difference was observed for omepra-
zole and lansoprazole, whereas no difference between all
genotypes was observed for rabeprazole [103]. This is
probably due to the metabolism of rabeprazole which
involves a non-enzymatic reduction [101].
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2.2.3 Psychotropic Agents
CYP2C19 is one of the major metabolic pathways for
several antidepressants, including imipramine, clomipra-
mine, citalopram, sertraline, fluoxetine, venlafaxine and
moclobemide [104]. Imipramine efficacy and adverse
effects are associated with the sum of the plasma concen-
trations of imipramine and its active metabolite desipra-
mine. The formation of the latter is mediated via
CYP2C19. Some authors reported an increase in the
imipramine/desipramine concentration in CYP2C19 PMs,
potentially resulting in an increased frequency of adverse
effects. For this reason, a dose reduction of 70 % of the
recommended dose or the selection of an alternative drug is
warranted [105].
Citalopram is metabolised primarily by CYP2C19 and
CYP3A4, and to a lesser extent by CYP2D6 [106]. Dif-
ferences in the PK properties of citalopram and escitalop-
ram have been reported in CYP2C19 PMs and IMs [88].
However, owing to the large therapeutic window of these
antidepressants, this does not appear to result in differences
in their side effects. Therefore, a dose adjustment is not
considered necessary. However, a recent publication
reported a case of escitalopram-induced serotonin syn-
drome due to CYP2C19 and CYP2D6 genetic polymor-
phisms and drug–drug interactions with CYP2C19 and
CYP3A4 inhibitors [105] (Table 2). Results from the
Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study, which included more than 1,000 patients,
showed that the *2 variant allele was associated with lower
odds of tolerance of citalopram (OR 0.60; 95 % CI
0.39–0.91; P = 0.02). Indeed, PMs may achieve high drug
serum levels, which in some patients may be associated
with lower drug tolerance. In the subset of subjects who
were tolerant of citalopram treatment, remission was
highest for CYP2C19 PMs, suggesting that PMs who are
able to tolerate citalopram may have favourable treatment
outcomes [107].
For sertraline, significant differences in PK parameters
have been reported in CYP2C19 PMs, requiring a 50 %
dose reduction in this population of patients [105].
2.3 CYP2C9
CYP2C9 exhibits a genetic polymorphism and, to date,
more than 35 allelic variants and a number of subvariants
have been described [108]. The two most common allelic
variants are CYP2C9*2 [109] and CYP2C9*3 [110]. Both
of these polymorphisms lead to a reduced activity of
CYP2C9. These two alleles are carried by approximately
35 % of Caucasians [111, 112] but are relatively rare in
Asian and African populations [113].
2.3.1 Vitamin K Antagonists
CYP2C9 is the major route of metabolism of vitamin K
antagonists such as warfarin, acenocoumarol and phen-
procoumone, drugs commonly used for thrombotic com-
plications (deep vein thrombosis, atrial fibrillation,
myocardial infarct). Warfarin is metabolised by several
cytochromes P450 but CYP2C9 is the major metabolic
pathway. The first correlation between polymorphisms of
CYP2C9, warfarin doses and the risk of bleeding was
observed in 1999 [114]. In this study, patients with the
CYP2C9*2 and CYP2C9*3 alleles required lower doses of
warfarin. This observation has since been reported in many
clinical studies [115–117] and seems to be especially
noticeable at the beginning of the anticoagulant treatment
[118–120]. Stabilisation of treatment is also a parameter
that was found to be influenced by polymorphisms of
CYP2C9. Among carriers of the CYP2C9*3 allele, the time
to reach treatment stability with warfarin or acenocoumarol
is longer [121, 122]. Once the dosage is stabilised, it
appears that CYP2C9 polymorphisms influence the effect
of oral anticoagulation to a lesser extent [123, 124]. In
some studies, it has also been reported that the occurrence
of supratherapeutic INRs was higher in patient carriers of
these polymorphisms [122, 125]. The CYP2C9*2 allele
seems to have less influence on the dose of acenocoumarol
or phenprocoumon compared to warfarin [121, 122, 126,
127]. However, some studies do show a need for decreased
doses of acenocoumarol in CYP2C9*2 carriers [128, 129].
Numerous guidelines have been published on the use of
pharmacogenomic tests in dosing of warfarin [130]. Two
online algorithms are recommended that both provide
reliable and very similar results [54, 131].
2.3.2 NSAIDs
In vitro studies have demonstrated that at least 18 NSAIDs
(namely aceclofenac, aspirin, azapropazone, celecoxib,
diclofenac, etodolac, flurbiprofen, ibuprofen, indomethacin,
lornoxicam, mefenamic acid, meloxicam, naproxen, phe-
nylbutazone, piroxicam, suprofen, tenoxicam and valdec-
oxib) are metabolised, mainly, or at least in part, by
CYP2C9 [132]. To date, the PK or PD consequences of
CYP2C9 polymorphisms have been studied for several
NSAIDs (celecoxib, diclofenac, flurbiprofen, ibuprofen,
lornoxicam, piroxicam and tenoxicam), with the PD studies
focusing mainly on adverse effects rather than on efficacy.
Results of these different studies are often controversial. A
retrospective trial (n = 218) assessed the association of
polymorphic CYP2C9 alleles and the risk of acute gastro-
intestinal (GI) bleeding in subjects receiving NSAIDs. The
frequency of CYP2C9 polymorphic alleles increased in
individuals with NSAIDs-induced acute gastric bleeding.
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The OR for bleeding was 2.5 for heterozygous and 3.7 for
homozygous carriers of mutated alleles when compared
with non-bleeding subjects. Unexpectedly, this observed
risk was associated with the CYP2C9*2 allele [133].
Another study (n = 26) identified a significantly higher
frequency of CYP2C9*1/*3 and CYP2C9*1/*2 carriers in
documented NSAID-related gastro-duodenal bleeding ver-
sus a matched control group. The presence of CYP2C9*3
was associated with a significant higher risk of bleeding
(OR 7.3) even though no CYP2C9*3/*3 carriers were
included in the study [134]. A more recent study with a
bigger sample (n = 188) also concluded that there was an
increased risk of GI bleeding when treated with NSAIDs
that was linked to the presence of the CYP2C9*3 allele
[135]. However, two other small (n = 23 and n = 26)
retrospective studies found no relationship between
NSAID-induced gastric ulceration and CYP2C9 genotype.
Again, no homozygote (*3/*3) patient was included in the
study [136, 137]. Even though risk of GI bleeding is clearly
linked to the dose of NSAID and that PK data show a
greater exposition to these drugs in carriers of the
CYP2C9*2 and/or CYP2C9*3 alleles, the actual in vivo
evidence on augmented risk of GI bleeding is controversial
and there is therefore no recommendation of dosage adap-
tation in mutated patients.
2.3.3 Sulfonylureas
Sulfonylureas, such as first-generation tolbutamide and
second-generation gliclazide, glyburide (also called gli-
benclamide) and glimepiride, are oral hypoglycaemic
agents used for the treatment of type 2 diabetes. They are
mainly metabolised by CYP2C9 [138], with a contribution
of CYP2C19 for several of these sulfonylureas [139, 140].
The PK properties of sulfonylureas have been evaluated in
few studies. For tolbutamide, mean oral clearances were
reduced for all healthy carriers of one or two *2 or *3
alleles, with a clearance of 0.15 l/h in homozygous carriers
of CYP2C9*3 compared to 0.97 l/h in wild-type subjects.
These PK differences did, however, not affect insulin and
glucose concentrations [141]. In homozygous subjects for
allele CYP2C9*3/*3, oral clearance of glyburide was
reduced by more than 50 % compared to wild-type subjects
and insulin serum levels at 12 h were significantly higher.
Presence of the CYP2C9*2 allele had only a slight influence
on these two parameters [142]. In another study, heterozy-
gous carriers of CYP2C9*3 showed a median total area
under the plasma concentration–time curve of 280 % and of
267 % for the values in CYP2C9*1/*1 carriers for glyburide
and glimepiride, respectively [143]. A study conducted on
type 2 diabetic patients, treated with either glimepiride,
gliclazide or glipizide, showed that carriers of CYP2C9*2
or *3 alleles were more prone to hypoglycaemic attacks
than wild-type subjects but this difference was only sig-
nificantly associated with gliclazide [144]. Even if there is a
clear PK relation between sulfonylureas and CYP2C9
polymorphisms, no adaptation of dosage is recommended
because of a mild risk of hypoglycaemia and the possibility
to monitor glucose plasma levels [54].
2.3.4 Angiotensin II Receptor Antagonists
Angiotensin II receptor antagonists, such as losartan, irbe-
sartan and candesartan, are used in the treatment of hyper-
tension and congestive heart failure. These drugs are
metabolised by CYP2C9; in the case of losartan, this
metabolism affords an active metabolite. Several studies
showed either a lower rate of oxidation of losartan into its
metabolite [145], a higher plasma AUC losartan/AUC
metabolite ratio [146] or a decreased level of the losartan
metabolite [147] in carriers of CYP2C9*2 and/or CYP2C9*3
alleles. In type 1 diabetic patients with nephropathy, the
change in systolic blood pressure was significantly greater in
non *3 carriers than in *3 carriers after 4 months [148]. For
irbesartan, a study in Chinese patients showed an increased
plasma concentration in the CYP2C9*3 carriers but without
any impact on the hypotensive effect [149]. However, a
greater reduction in blood pressure in carriers of the *1/*2
and the *1/*3 genotypes compared with wild-type subjects
was observed with irbesartan in a Swedish population [150].
There is no recommendation for a dose adaptation when
these angiotensin II receptor antagonists are prescribed to
carriers of mutated alleles of CYP2C9.
2.3.5 Phenytoin
Phenytoin is a commonly used antiepileptic drug. It is mainly
metabolised by CY2C9 with a minor contribution of
CYP2C19. Patient carriers of at least one CYP2C9*2 or
CYP2C9*3 allele with plasma concentrations in the thera-
peutic range needed approximately a third lower daily dose of
phenytoin than wild-type patients (199 versus 314 mg/day,
respectively) [151]. Similar results were found in Turkish
[152], Japanese [153] and Taiwanese populations [154].
Regarding the evaluation of an increased toxicity of phenytoin
in CYP2C9 mutated patients, a small study showed an
increased incidence of cutaneous reactions among carriers of
CYP2C9*3 compared to wild-type patients [155]. Another
study showed an increased risk of neurological adverse
reactions (defined as symptoms such as dizziness, nystagmus,
ataxia, slurred speech, lethargy and mental confusion) in a
Southern Indian population when they were carriers of the
CYP2C9*3 allele [156]. Dosage adaptation has been recom-
mended for phenytoin in CYP2C9 mutated patients, with a
dose reduction of 25 % for *1/*2 and *1/*3 carriers and of
50 % for *2/*2, *2/*3 and *3/*3 carriers [28].
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3 Genotyping and Phenotyping Techniques
Besides the quantification of the circulating drug concen-
trations (therapeutic drug monitoring), two approaches are
now available to help personalise drug therapies.
Phenotyping and genotyping tests are used in clinical
practice to identify variations in CYP enzymatic activities or
CYP allelic variants. They may help in predicting the right
dose for the right patient, and anticipating toxicities or
therapeutic inefficacies. Furthermore, they may allow the
distinction between a compliance problem and an UM phe-
notype or between a drug overdose and a metabolic defect.
Genotyping allows precise determination of the indi-
vidual DNA sequence and analysis of functional genetic
mutations coding for specific enzymes. It offers the pos-
sibility to predict the phenotype based on the alleles
identified providing that the relationship between genotype
and phenotype has been established. Genotyping is not yet
available for all CYP and its major drawback is the inca-
pacity to measure the influence of the environmental fac-
tors such as drug–drug interactions on the enzymatic
activity. CYP phenotyping provides information on the
real-time (in vivo) activity of CYP enzymes and may
therefore provide the most clinically relevant information
as it reflects a combination of genetic, environmental and
endogenous factors [157].
3.1 Genotyping
Classical molecular biology methods analyse one allele at a
time and use polymerase chain reaction (PCR) to amplify
DNA coupled with post-PCR detection methods such as
restriction fragment length polymorphism (RFLP) after
hydrolysis with restriction enzymes or fluorescing probes
specific for each allele [158]. This implies that only a small
subset of variant alleles are usually analysed which can
therefore reduce the power of phenotype prediction for
some groups of metabolisers. Furthermore the wild-type
allele (*1) is assumed by default and not specifically tested.
Real-time PCR-based assay methods for most clinically
important variant genes of CYP2C9, CYP2C19 and
CYP2D6 are now available. Depending on the number of
SNPs to be screened, multiplexing approaches have also
been developed. The microarray technologies offer the
advantage of allowing simultaneous determination of var-
ious alleles, as well as being rapid, reliable, accurate and
easy to perform [159].
3.1.1 AmpliChip CYP450 GeneChip
This is an oligonucleotide microarray hybridisation method
for genotyping CYP2D6 and CYP2C19 that has been
developed by Roche Molecular Systems and Affymetrix. It
was the first clinically available tool based on microarray
technology and was granted market approval by the FDA
in 2004. A total of 15,000 oligonucleotide probes are
included in the microarray that allow simultaneous and
multiple allele testing for 20 alleles of CYP2D6 (*1, *2, *3,
*4, *5, *6, *7, *8, *9, *10, *11, *15, *17, *19, *20, *29,
*35, *36, *40 and *41) as well as 7 CYP2D6 duplications
(*1 9 N, *2 9 N, *4 9 N, *10 9 N, *17 9 N, *35 9 N
and *41 9 N) and 3 CYP2C19 alleles (*1, *2 and *3)
[160]. The test is based on five major processes: PCR
amplification of purified DNA, labelling of the amplified
product, hybridisation of the labelled amplified product to a
microarray and staining of the bound products, scanning of
the microarray and interpretation of the phenotype by
software using an algorithm [161]. This test does not
determine the exact number of extra copies of CYP2D6
alleles. The overall genotype call rate was 99.3 % for 403
tested samples. The performance of the AmpliChip in
predicting CYP2D6 phenotype was assessed (n = 165) and
an overall 80 % coherence was obtained. Phenotype pre-
diction was optimal for PM (sensitivity and specificity
100 %) and satisfactory for EM (sensitivity 95 %, speci-
ficity 47 %) and IM (sensitivity 42 %, specificity 97 %)
but discrepancies were observed for UM prediction (sen-
sitivity 6 %, specificity 99 %) [162].
3.1.2 Luminex Tag-It Mutation Detection Kit
The detection kit marketed by Luminex uses a micro-
sphere-based universal array genotyping platform [160].
The Luminex xTAG CYP2D6 kit was approved by the
FDA to detect the following alleles: *1, *2, *3, *4, *5, *6,
*7, *8, *9, *10, *11, *15, *17, *29, *35, *41, 9N. How-
ever it does not specify if the allele is duplicated and it is
not associated with phenotype prediction algorithm soft-
ware. Seven alleles can be detected for CYP2C19 (*2, *3,
and the rare *4, *5, *6, *7, *8), and five alleles for CYP2C9
(*2, *3, *4, *5 and *6).
3.1.3 iPLEX ADME
Three panels have been developed by Sequenom: PGx
panel, CYP2C9/VKORC1 panel and CYP2C19 panel.
The iPLEX ADME PGx panel simultaneously analyses
192 SNPs in 36 genes such as CYP1A, 2A6, 2B6, 2C19,
2C8/9, 2D6, 2E1, 3A4/5, phase II drug-metabolising
enzymes and drug transporters. Analysis is provided by the
MassARRAY system.
Targeted assay panels can be created using the Assay
Explorer program [163].
The iPLEX ADME CYP2C9/VKORC1 panel is a set of
36 SNPs for CYP2C9 and 9 SNPs for VKORC1. The iPLEX
ADME CYP2C19 panel analyses 31 SNPs for CYP2C19.
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3.1.4 INFINITI CYP2C19 Assay
The assay marketed by Autogenomics uses a hybridisation
capture array with instrument-performed automated
detection of multiple PCR products. PCR amplification is
done offline while the rest of the processes are automated
by the AutoGenomics INFINITI Analyzer. The assay is
available in two formats: one sample per microarray chip
or four samples. It identifies only the CYP2C19 *2, *3 and
*17 alleles and corresponding genotype polymorphisms.
The assay report lists the alleles and provides the genotype
detected (wild type, mutant, heterozygote). The call rate
reported by the manufacturer is greater than 90 % with no
incorrect call rate [164].
3.1.5 eSensor Warfarin Sensitivity Test
This DNA hybridisation and electrochemical detection
test is marketed by GenMark and allows detection and
genotyping of CYP450 2C9 (*2 and *3) and VKORC1
(-1639G[A), with a result produced in approximately
3.5 h [165].
3.1.6 Spartan RX CYP2C19 System
This kit identifies carriers of the CYP2C19*2 allele using a
cheek swab and adding sample to a cartridge then placing
into a Spartan RX machine, printing a result in 1 h [166].
3.2 Phenotyping
Phenotyping consists of the administration of a ‘‘model’’ or
probe drug metabolised by an individual specific CYP. The
assessment of different PK parameters of the probe drug and
its metabolites or the determination of a ratio between the
drug and its metabolite (metabolic ratio, MR) allow the
definition of an individual metabolic profile. When a
genetic polymorphism is clearly defined for a specific CYP
isoform, the phenotyping tests permit the distinction
between individuals [167]. The individual phenotyping
involves administration of one CYP-specific probe, whereas
the simultaneous phenotyping involves concomitant
administration of multiple specific probes (probes cocktail)
and allows the concurrent detection of the activity of mul-
tiple enzymes [168]. A phenotyping cocktail made of a
mixture of probes has some advantages because a simulta-
neous determination of several CYP activities in a single
test is possible, avoiding the influence of variability over
time on phenotyping results [169–173]. Several drugs have
been documented as CYP2D6 phenotyping probes. Debr-
isoquine and sparteine have been frequently used, but
concerns about their availability and safety have limited
their use [174]. Recently, dextromethorphan has been
considered as the probe of choice for CYP2D6 activity
assessment by measuring the metabolic ratio DEM/DORtotal
in urine after 8 h [175–177]. Omeprazole is the preferred
probe test for CYP2C19 phenotyping [178–180]. In all of
the proposed cocktails caffeine was found to be the best
probe drug for CYP1A2 phenotyping [181–183]. Several
probes have been proposed for CYP3A activity assessment,
including erythromycin, dapsone and endogenous cortisol.
Midazolam is also a standard probe for this CYP owing to
its selectivity and absence of transport by P-glycoprotein,
which is also subject to high interindividual variability.
However, oral administration of midazolam does not allow
differentiation between CYP3A4 and CYP3A5 [184, 185].
Diverse probe drugs have been proposed to measure
CYP2C9 enzymatic activity. These include mostly warfa-
rin, tolbutamide, losartan and flurbiprofen [186]. For
CYP2B6, the European Medicines Agency (EMA) recom-
mend bupropion as a potential probe drug for CYP2B6
assessment [187]. One of the major drawbacks of pheno-
typing is the occurrence of side effects and PK–PD inter-
actions between the probes when therapeutic doses of
probes are used. The probability of such interactions and
adverse effects may be minimised by the use of low dose
probe drugs. Micrococktails using microdoses of each
probe drug are therefore now being developed.
Another drawback of the phenotyping methods is the
tedious sample collection. In fact, most validated cocktails
need more than one blood sample and urine collection for
at least 8 h. Alternative sampling procedures are continu-
ously developed and optimised in order to improve
patients’ comfort and reduce the quantity of collected fluid.
Recently, a dried blood spot (DBS) sampling procedure
was validated for the individual assessment of CYP2C9
activity using flurbiprofen as probe drug [188]. This pro-
cedure has the advantage of being less invasive, more cost-
effective and easier to transport and store in comparison to
the standard venous blood sampling [189]. Owing to its
non-invasiveness and the low volume required, the DBS
procedure is perfectly adapted for the evaluation of the PK
properties of a drug in clinical studies or for the evaluation
of the enzymatic activity [190].
4 Conclusion
We have presented here the relevant data where genotyping
and phenotyping may be considered, and the guidelines
developed when available. Guidelines have been published
for codeine and CYP2D6 [53], clopidogrel and CYP2C19
[92] and warfarin and CYP2C9 [130], as well as for some
TCAs and SSRIs (Table 3).
Over the last decade, the knowledge of pharmacogenetic
modulators has increased so that individualised pre-emptive
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therapy adjusted to the patient’s genetic background could
get closer to reality [191]. Furthermore, the American and
European regulatory agencies (FDA and EMA) have
recognised the clinical value of pharmacogenetics and have
developed guidelines for industry concerning pharmacog-
enomic data submission with new drugs. They now
recommend updating drug labels when compelling data are
present [192]. Better therapeutic outcome has been asso-
ciated with the choice of treatment and/or dose adjustment
according to patient’s genetic make-up in the field of
oncology, cardiovascular medicine, psychiatrics and pain
[193].
However, the use of pharmacogenetics has remained
limited because of the paucity of studies showing that
pharmacogenetic testing leads to improved clinical out-
comes. So far, pharmacogenetics has been mainly used in a
retrospective manner in order to identify and explain cau-
ses of abnormal responses (either inefficacy or toxicity) in
individual patients.
Regarding drugs already on the market, pharmacoge-
netic-based dosing could be used if large prospective
studies showed the benefit of pre-emptive genotyping
associated with better outcomes, but these studies are so far
very sparse.
A detailed knowledge of pharmacology is a prerequisite
for application in clinical practice, and physicians might
find it difficult to interpret the clinical value of pharma-
cogenetic test results. Guidelines that link the result of a
pharmacogenetic test to therapeutic recommendations
might help to overcome these problems. Slowly, peer-
reviewed drug-dosing guidelines based on individual
genotypes are being published. These guidelines are
updated periodically by PharmGKB, a comprehensive
resource that curates knowledge about the impact of
genetic variation on drug response for clinicians and
researchers, from the accumulation of gene–drug knowl-
edge to the implementation of pharmacogenomics in the
clinic. These guidelines are available on the PharmGKB
website [54].
In addition, new diagnostic techniques made safer and
easier should allow quicker diagnosis of metabolic variations.
Therefore, though it may appear premature to recom-
mend the application of a single genetic test before the start
of the treatment; pharmacogenetics might already help to
identify the right molecule for the right patient.
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